Allison Stocker
Dermatology · San Antonio, TXNPI 1134149669
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.0% of the total across 193 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by AbbVie at 37.7% of the total.
Across 193 payments — averaging $67.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- UCB, Inc.$1K
- Janssen Scientific Affairs, LLC$810
- Ortho Dermatologics, A Division Of Bausch Health US, LLC$669
- Galderma Laboratories, L.p.$654
- Lilly USA, LLC$543
- plus $4K from 20 others
What the payments were for
- Speaking & faculty fees$5044%
- Food & beverage$12,46196%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 107 | $4,891 |
| UCB, Inc. | 8 | $1,013 |
| Janssen Scientific Affairs, LLC | 7 | $810 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 6 | $669 |
| Galderma Laboratories, L.p. | 11 | $654 |
| Lilly USA, LLC | 11 | $543 |
| Regeneron Healthcare Solutions, Inc. | 4 | $488 |
| E.r. Squibb & Sons, L.L.C. | 5 | $462 |
| Arcutis Biotherapeutics, Inc. | 3 | $419 |
| Pfizer | 4 | $408 |
| Sanofi | 3 | $400 |
| Dermavant Sciences, Inc. | 3 | $360 |
| Revance Therapeutics, Inc. | 3 | $300 |
| VYNE Pharmaceuticals Inc. | 2 | $262 |
| Sun Pharmaceutical Industries Inc. | 3 | $256 |
| Almirall LLC | 1 | $161 |
| Organon | 2 | $152 |
| Aclaris Therapeutics, Inc. | 1 | $125 |
| Boehringer Ingelheim | 1 | $122 |
| Verrica Pharmaceuticals Inc. | 1 | $113 |
| Incyte Corporation | 1 | $110 |
| Journey Medical Corporation | 1 | $103 |
| LEO Pharma Inc. | 1 | $69 |
| Johnson & Johnson | 2 | $58 |
| Mission Pharmacal Company | 1 | $19 |
| Genentech USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,981 in reported general payments places this provider in the 75th percentile of 1,098 dermatology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ElmironPentosan Polysulfate Sodium | 12 | $10,804 |
| Doxycycline Hyclate | 16 | $556 |
| Triamcinolone Acetonide | 15 | $72 |
Paid to pharmacies, not to this prescriber.
Other dermatology in San Antonio
- William CragunSan Antonio$2.2M
- Emily BeckerSan Antonio$1.2M
- Lindsey FinkleaSan Antonio$435K
- John BrowningSan Antonio$351K
- Vivian BucaySan Antonio$241K
- Annabelle GarciaSan Antonio$215K
- Edward LainAustin$2.5M
- Alpesh DesaiHouston$1.6M
- Craig TellerBellaire$1.3M
- Jennifer CatherDallas$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.